Efficacy and Safety of Rivaroxaban in the Prevention of Venous Thromboembolism in Glioma Patients
Status:
Recruiting
Trial end date:
2025-02-28
Target enrollment:
Participant gender:
Summary
Glioma is a common brain tumor with a high risk of venous thromboembolism during treatment,
especially in the months after surgery. Postoperative lower extremity dyskinesia in patients
with gliomas is considered as a high-risk factor for venous thromboembolism. Rivaroxaban, as
an oral anticoagulants, has similar effect in the prevention and treatment of tumor-related
venous thromboembolism compared to low molecular weight heparin. Given the lack of
prospective supporting data, the efficacy and safety of rivaroxaban in the prevention of
postoperative venous thromboembolism in glioma patients with postoperative lower extremity
dyskinesia need to be established.